Literature DB >> 8608647

Significance of IL-1beta and IL-1 receptor antagonist (IL-1Ra) in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis (DPB).

J Kadota1, Y Matsubara, Y Ishimatsu, M Ashida, K Abe, R Shirai, K Iida, K Kawakami, H Taniguchi, T Fujii, M Kaseda, S Kawamoto, S Kohno.   

Abstract

We evaluated the effect of erythromycin therapy on pulmonary function tests and the airway inflammatory response of patients with DPB. The number of neutrophils in BALF obtained from DPB patients was significantly higher than that of healthy volunteers. Treatment with erythromycin (600 mg/day for 12.9+/-9.5 months (mean +/- s.d.)) significantly reduced the total number of cells and neutrophils in the airway, and significantly improved pulmonary function tests. The levels of IL-1beta and IL-8 were significantly higher in DPB compared with healthy volunteers (P<0.05, P<0.05, respectively). IL-1Ra in patients is considered to have a weak inhibitory activity for IL-1beta, with approximately five-fold concentration of IL-1beta compared with that in healthy volunteers (approx. nine-fold concentration of IL-1beta). Erythromycin therapy significantly reduced these cytokines to levels comparable to those of healthy volunteers, and produced a trend toward reduction in the level of IL-1Ra in BALF. The level of IL-1beta correlated significantly with the concentration of neutrophils in BALF (r=0.72, P<0.01), as well as with the level of IL-1Ra (r=0.688, P<0.05) and IL-8 (r=0.653, P<0.05). A nearly significant or significant correlation was observed between the concentration of neutrophils and levels of IL-1Ra or IL-8 in BALF (r=0.526, P=0.053 or r=0.776, P<0.01, respectively). There was also a significant relationship between FEV(1) and the concentration of neutrophils in BALF (r=0.524, P<0.05). Our results suggest that the relative amounts of IL-1beta and IL-1Ra or IL-8 may contribute, at least in part, to the neutrophil-mediated chronic airway inflammation in patients with chronic airway disease, and long-term erythromycin therapy may down-regulate the vigorous cycle between the cytokine network and neutrophil accumulation, with resultant reduction of neutrophil-mediated inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608647      PMCID: PMC2200364          DOI: 10.1111/j.1365-2249.1996.tb08303.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  33 in total

1.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

2.  [Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis].

Authors:  S Kudoh; T Uetake; K Hagiwara; M Hirayama; L H Hus; H Kimura; Y Sugiyama
Journal:  Nihon Kyobu Shikkan Gakkai Zasshi       Date:  1987-06

Review 3.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

4.  Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein.

Authors:  D B Carter; M R Deibel; C J Dunn; C S Tomich; A L Laborde; J L Slightom; A E Berger; M J Bienkowski; F F Sun; R N McEwan
Journal:  Nature       Date:  1990-04-12       Impact factor: 49.962

5.  Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration, and leukotriene B4 biosynthesis.

Authors:  M K Thomsen; C G Larsen; H K Thomsen; D Kirstein; T Skak-Nielsen; I Ahnfelt-Rønne; K Thestrup-Pedersen
Journal:  J Invest Dermatol       Date:  1991-02       Impact factor: 8.551

6.  Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4.

Authors:  R Lawrence; T Sorrell
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

7.  Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy.

Authors:  O Sakito; J Kadota; S Kohno; K Abe; R Shirai; K Hara
Journal:  Respiration       Date:  1996       Impact factor: 3.580

8.  Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.

Authors:  J B Richman-Eisenstat; P G Jorens; C A Hébert; I Ueki; J A Nadel
Journal:  Am J Physiol       Date:  1993-04

9.  A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis.

Authors:  J Kadota; O Sakito; S Kohno; H Sawa; H Mukae; H Oda; K Kawakami; K Fukushima; K Hiratani; K Hara
Journal:  Am Rev Respir Dis       Date:  1993-01

10.  Regulation of cytokine secretion by cystic fibrosis airway epithelial cells.

Authors:  C Ruef; D M Jefferson; S E Schlegel-Haueter; S Suter
Journal:  Eur Respir J       Date:  1993-11       Impact factor: 16.671

View more
  5 in total

Review 1.  Erythromycin and diffuse panbronchiolitis.

Authors:  H Koyama; D M Geddes
Journal:  Thorax       Date:  1997-10       Impact factor: 9.139

2.  Characterization of CD44 expressed on alveolar macrophages in patients with diffuse panbronchiolitis.

Authors:  S Katoh; Y Matsubara; H Taniguchi; K Fukushima; H Mukae; J Kadota; S Matsukura; S Kohno
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 3.  Autoinflammatory disease in the lung.

Authors:  Thomas Scambler; Jonathan Holbrook; Sinisa Savic; Michael F McDermott; Daniel Peckham
Journal:  Immunology       Date:  2018-04-19       Impact factor: 7.397

4.  NF-κB mediates IL-1β- and IL-17A-induced MUC5B expression in airway epithelial cells.

Authors:  Tomoyuki Fujisawa; Mary Mann-Jong Chang; Sharlene Velichko; Philip Thai; Li-Yin Hung; Fei Huang; Newton Phuong; Yin Chen; Reen Wu
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-08       Impact factor: 6.914

5.  Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm.

Authors:  Tomoyuki Fujisawa; Sharlene Velichko; Philip Thai; Li-Yin Hung; Fei Huang; Reen Wu
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.